NCT00545818

Brief Summary

The purpose of this study is to see if OsseoSpeed™ implant 6 mm long is effective for rehabilitation of edentulism and if so, how it compares with OsseoSpeed™ implant 11 mm long. The primary hypothesis is that the alteration in bone level is equal in patients randomized to 6 mm as to patients randomized to 11 mm implants.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
97

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Nov 2007

Longer than P75 for not_applicable

Geographic Reach
5 countries

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 16, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 17, 2007

Completed
15 days until next milestone

Study Start

First participant enrolled

November 1, 2007

Completed
8.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
4.1 years until next milestone

Results Posted

Study results publicly available

May 19, 2020

Completed
Last Updated

May 19, 2020

Status Verified

May 1, 2020

Enrollment Period

8.5 years

First QC Date

October 16, 2007

Results QC Date

April 14, 2020

Last Update Submit

May 7, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Radiological Assessments of Marginal Bone Level Alteration

    Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal Bone Level expressed in millimeters at the 5 year follow-up visit compared to values obtained at delivery of temporary restoration i.e. loading (baseline). Positive value = bone gain, Negative value = bone loss.

    Evaluated from implant installation to 5 years follow-up after implant placement

Secondary Outcomes (4)

  • Overall Implant Survival

    Evaluated 5 years after implant placement

  • Evaluation of the Periimplant Mucosa Condition - By Assessment BoP

    Measured at the 5-year follow-up visit after loading

  • Evaluation of the Periimplant Mucosa Condition - By Assessment of Change in PPD

    Evaluated at implant loading and at the 5-year follow-up visit.

  • Presence of Plaque

    Evaluated at the 5-year follow-up visit after loading.

Study Arms (2)

Group-1, Implant length 6 mm

EXPERIMENTAL

Subjects treated with OsseoSpeed™ implant, length: 6 mm

Device: OsseoSpeed™ length 6 mm

Group-2, Implant length 11 mm

OTHER

Subjects treated with OsseoSpeed™ implant, length: 11 mm

Device: OsseoSpeed™ length 11 mm

Interventions

OsseoSpeed™ dental implant, length: 6 mm

Group-1, Implant length 6 mm

OsseoSpeed™ dental implant, length: 11 mm

Group-2, Implant length 11 mm

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provision of informed consent
  • Aged 20-70 years at enrolment
  • History of edentulism in the study area of at least four months
  • Neighboring tooth/teeth to the planned bridge must have natural root(s)
  • Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in contact with the planned bridge.
  • Deemed by the investigator to have a bone height of at least 11 mm and a bone width of minimum 6 mm
  • Deemed by the investigator as likely to present an initially stable implant situation

You may not qualify if:

  • Unlikely to be able to comply with study procedures, as judged by the investigator
  • Earlier graft procedures in the study area
  • Uncontrolled pathologic processes in the oral cavity
  • Known or suspected current malignancy
  • History of radiation therapy in the head and neck region
  • History of chemotherapy within 5 years prior to surgery
  • Systemic or local disease or condition that could compromise post-operative healing and/or osseointegration
  • Uncontrolled diabetes mellitus
  • Corticosteroids or any other medication that could influence post-operative healing and/or osseointegration
  • Smoking more than 10 cigarettes/day
  • Present alcohol and/or drug abuse
  • Involvement in the planning and conduct of the study (applies to both Astra Tech staff and staff at the study site)
  • Previous enrolment in the present study.
  • Severe non-compliance to protocol as judged by the investigator and/or Astra Tech
  • Simultaneous participation in another clinical study, or participation in a clinical study during the last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

USC School of Dentistry

Los Angeles, California, 90089-0641, United States

Location

The University of Iowa, College of Dentistry

Iowa City, Iowa, 52242-1010, United States

Location

School of Dental Science, University of Melbourne

Melbourne, Victoria, 3010, Australia

Location

Praktijk De Mondhoek

Apeldoorn, 7315, Netherlands

Location

Dept. of Parodontology, Göteborg University

Gothenburg, SE 405 30, Sweden

Location

King's College London Dental Institute at Guy's King's and St Thomas' Hospitals

London, SE1 9RT, United Kingdom

Location

Related Publications (2)

  • Gulje F, Abrahamsson I, Chen S, Stanford C, Zadeh H, Palmer R. Implants of 6 mm vs. 11 mm lengths in the posterior maxilla and mandible: a 1-year multicenter randomized controlled trial. Clin Oral Implants Res. 2013 Dec;24(12):1325-31. doi: 10.1111/clr.12001. Epub 2012 Sep 3.

  • Zadeh HH, Gulje F, Palmer PJ, Abrahamsson I, Chen S, Mahallati R, Stanford CM. Marginal bone level and survival of short and standard-length implants after 3 years: An Open Multi-Center Randomized Controlled Clinical Trial. Clin Oral Implants Res. 2018 Aug;29(8):894-906. doi: 10.1111/clr.13341. Epub 2018 Jul 12.

MeSH Terms

Conditions

Jaw, Edentulous, Partially

Condition Hierarchy (Ancestors)

Jaw, EdentulousJaw DiseasesMusculoskeletal DiseasesStomatognathic DiseasesMouth, EdentulousMouth DiseasesTooth Diseases

Results Point of Contact

Title
Manager Global Clinical Research
Organization
Dentsply Sirona Implants, Mölndal, SWEDEN

Study Officials

  • Anna-Karin Lundgren

    Direktor Clinical Research, Dentsply Sirona Implants, Mölndal, SWEDEN

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2007

First Posted

October 17, 2007

Study Start

November 1, 2007

Primary Completion

May 1, 2016

Study Completion

May 1, 2016

Last Updated

May 19, 2020

Results First Posted

May 19, 2020

Record last verified: 2020-05

Locations